Affordable Access

Targeting CDCA3 enhances sensitivity to platinum-based chemotherapy in non-small cell lung cancer (Conference Abstract)

Authors
  • Adams, Mark
  • Burgess, Joshua
  • Richard, Derek
  • O'Byrne, Ken
Publication Date
Jan 01, 2017
Source
Queensland University of Technology ePrints Archive
Keywords
License
Unknown

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide with a 5 year survival rate of 15%. Non-small cell lung cancer (NSCLC) is the most commonly diagnosed form of lung cancer. Cisplatin-based regimens are currently the most effective chemotherapy for NSCLC, however, chemoresistance poses a major therapeutic problem. New and reliable strategies are required to avoid drug resistance in NSCLC. Cell division cycle associated 3 (CDCA3) is a key regulator of the cell cycle. CDCA3 modulates this process by enabling cell entry into mitosis through degradation of the mitosis-inhibitory factor WEE1.

Report this publication

Statistics

Seen <100 times